欢迎访问《现代生物医学进展》编辑部！

目的：探讨抗血管生成药物Bevacizumab 联合吉西他滨对人肝癌裸鼠皮下移植瘤生长的抑制作用。方法：构建人肝癌细胞 HepG2 裸鼠皮下移植瘤模型，随机分为空白对照组、Bevacizumab 组、吉西他滨组和联合用药组。观察用药前后肿瘤体积，绘制肿瘤生长曲线；应用免疫组化检测肿瘤微血管密度(MVD)；Western Blot 检测Bcl-2 蛋白的表达。结果：Bevacizumab 和吉西他滨单药均能抑制肿瘤生长，两药联合疗效明显增强(P =0.000)。与对照组和吉西他滨组相比，Bevacizumab 组和联合用药组能明显抑制肿瘤血管生成，MVD 值均明显降低,以联合用药组最为明显( P 均0.000) 。Bevacizumab 和吉西他滨单药均能下调Bcl-2 的表达，两药联合下调作用明显增强。结论：Bevacizumab 联合吉西他滨能增强对人肝癌裸鼠移植瘤的生长及微血管生成的抑制作用，其机制可能与调控Bcl-2 的表达有关。

英文摘要:

Objective: To investigate inhibitory effect of Bevacizumab combined with gemcitabine against HepG2 hepatocellul ar carcinoma (HCC) tumor xenografts. Methods: Established HepG2 HCC xenograft models. Mice were divided into four groups: untreated control group,Bevacizumab treated group,gemcitabine treated group and combination treatment group. Tumor volumes were recorded and microvessel density (MVD) was examined by immunohistochemistry.The expression of Bcl-2 was evaluated by western blot. Results: Bevacizumab and gemcitabine alone inhibits the growth of HepG2 HCC tumor xenografts. The efficacy of combination was significantly better than Bevacizumab or gemcitabine administered alone (P =0.000). The immunohistochemistry results showed that the MVD were reduced in Bevacizumab group, especially in combination groups ( P=0.000).In addition, Bevacizumab and gemcitabine alone reduced Bcl-2 expression in tumor tissues,especially in combination groups. Conclusion: Bevacizumab combined with gemcitabine can greatly inhibit the growth and angiogenesis of tumor in HCC xenograftmodels via an inhibition of Bcl-2 expression possibly.

View Full Text View/Add Comment Download reader